Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Drugs Aging. 2023 Nov;40(11):991-1007. doi: 10.1007/s40266-023-01068-8. Epub 2023 Oct 20.
Age-related macular degeneration (AMD) is one of the main causes of visual impairment and severe visual loss, and can progress to two advanced forms-neovascularization and atrophic. The field of anti-AMD drugs has undergone huge developments in recent years, from single-target intravitreal administration to current clinical studies with multi-target and non-invasive agents, offering interesting new pharmacological opportunities for the treatment of this disease. Hence, we summarize some of the approved anti-vascular endothelial growth factor (VEGF) drugs for neovascular AMD, especially their structural characteristics, clinical manifestations, dosing regimens, and safety issues of the anti-VEGF drugs highlighted. In addition, advances in atrophic AMD drug research are also briefly described.
年龄相关性黄斑变性（AMD）是导致视力损害和严重视力丧失的主要原因之一，可进展为两种晚期形式：新生血管形成和萎缩。近年来，抗 AMD 药物领域取得了巨大发展，从单一靶点玻璃体内给药到目前多靶点和非侵入性药物的临床研究，为该疾病的治疗提供了有趣的新药理机会。因此，我们总结了一些已批准用于治疗新生血管性 AMD 的抗血管内皮生长因子（VEGF）药物，特别是它们的结构特征、临床表现、给药方案和抗 VEGF 药物的安全性问题。此外，还简要描述了萎缩性 AMD 药物研究的进展。
